Dr. Kuvshinoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm and Carlton St
Buffalo, NY 14263Phone+1 716-845-2300Fax+1 716-845-1278
Summary
- As Chief Medical Officer I provide leadership and resources to enhance the quality of healthcare delivery at Roswell Park Cancer Institute. I work closely with Medical Staff Leadership to ensure that our patients are getting the most up-to-date, evidenced based, and patient-centered care. My clinical and research interest is in cancers of the liver, biliary tract, pancreas, and neuroendocrine (carcinoid) origin. This includes both metastatic and primary liver tumors. Use of ablation techniques for liver tumors including radiofrequency, microwave, and nanoknife. Minimally invasive (laparoscopic) resection of liver tumors and pancreas tumors. Also research and administrative interest in computer simulation of liver cancer, quality, performance improvement, and healthcare outcomes in surgery and oncology.
Education & Training
- Yale UniversityMBA, Health Care, 2006 - 2008
- Memorial Sloan-Kettering1993 - 1995
- University Hospital The1986 - 1993
- University of Maryland School of MedicineClass of 1986, MD, Cum Laude
Certifications & Licensure
- NY State Medical License 1993 - 2025
- OH State Medical License 1989 - 1994
- American Board of Surgery Surgery
- Memorial Sloan Kettering Cancer CenterSurgical Oncology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons, 1995
Publications & Presentations
PubMed
- 267 citationsNeuroendocrine tumors, version 1.2015Matthew H. Kulke, Manisha H. Shah, Al B. Benson, Emily K. Bergsland, Jordan Berlin
Journal of the National Comprehensive Cancer Network. 2015-01-01 - 33 citationsMultidisciplinary Cancer Conferences for Gastrointestinal Malignancies Result in Measureable Treatment Changes: A Prospective Study of 149 Consecutive PatientsJacqueline Oxenberg, Wesley A. Papenfuss, Iyare Esemuede, Kristopher Attwood, Marko Simunovic
Annals of Surgical Oncology. 2015-05-01 - 35 citationsHigh-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumorsManpreet K. Chadha, Jeffrey Lombardo, Terry Mashtare, Gregory E. Wilding, Alan Litwin
Anticancer Research. 2009-10-01
Press Mentions
- Decisions to Stray from Clinical Oncology Pathways Are Often Justified, Roswell Park Analysis ShowsMay 29th, 2020
- Roswell Park Appoints Chief Medical Officer, Four New Chiefs Leading Key Clinical ProgramsMarch 5th, 2024
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: